Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma

Hanlon Sia, Vinu Menon, Andrew Garton, Eileen Wolff, Tejas Shah, Colleen Charpentier, Dominique Duchesne, Maria Pihlgren, Jeppe Koch-Olsen, Adam Drake, Mario Perro, Eugene Zhukovsky, Lida Pacaud, Cyril Konto

Blood (2023) 142 (Supplement 1): 3396.

https://doi.org/10.1182/blood-2023-187106

Published: 2023

Journal Articles

Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 6574.

https://doi.org/10.1182/blood-2023-181546

Published: 2023

Journal Articles

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma

Blood (2023) 142 (3): 260–273.

https://doi.org/10.1182/blood.2022019451

Published: 2023

Includes: Supplemental data

Journal Articles

ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

Blood (2022) 140 (Supplement 1): 858–859.

https://doi.org/10.1182/blood-2022-159353

Published: 2022

Journal Articles

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 73.

https://doi.org/10.1182/blood-2021-145586

Published: 2021

Journal Articles

Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels

Archana Shrestha, Mengna Chi, PhD, Kimberly Wagner, Adam Drake, Keertik Fulzele, PhD, Sylvie Guichard, Punam Malik, MD

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-140875

Published: 2020

Journal Articles

Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects

Theodosia A. Kalfa, MD PhD, Frans A Kuypers, PhD, Marilyn J. Telen, MD, Punam Malik, MD, Diamantis G. Konstantinidis, PhD BSc, Jeremy H. Estepp, MD, Hyon J. Kim, MD PhD, Santosh L. Saraf, MD, Lindsey Wilson, Maria D Ribadeneira, PhD, Sanjeev Forsyth, Patricia Schroeder, Adam Drake, Olga Polyanskaya, Patrick Kelly, MD, Lukasz Biernat, MD

Blood (2019) 134 (Supplement_1): 616.

https://doi.org/10.1182/blood-2019-121889

Published: 2019

Journal Articles

Drug-Induced Cytokine Release Sensitizes Protective Tumor Microenvironments to Antibody- Mediated Therapy

Christian P. Pallasch, MD, Leskov Ilya, MD, PhD, Yadira M Soto, Christian J. Braun, MD, Nadine Kutsch, MD, Adam Drake, PhD, Lukas P. Frenzel, MD, Bettina Iliopoulou, PhD, Nico van Rooijen, PhD, Clemens Wendtner, MD, Michael Hallek, MD, Jianzhu Chen, PhD, Michael T Hemann, PhD

Blood (2012) 120 (21): 1335.

https://doi.org/10.1182/blood.V120.21.1335.1335

Published: 2012

NARROW

A Phase 1, First-in-Human, Dose Escalation and Dose-Expansion Study of a BCMAxCD38xCD3 Targeting Trispecific Antibody ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma

Integrated Preclinical Data Analysis of ISB 2001 Enables Optimal Starting Dose Selection for a First-in-Class Trispecific T Cell Engager Phase1 Study in Multiple Myeloma

Preclinical characterization of ISB 1342, a CD38 × CD3 T-cell engager for relapsed/refractory multiple myeloma

ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma

Oral Administration of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, Has Potent Anti-Sickling Effects in a Sickle Cell Anemia (SCA) Mouse Model, Resulting in Improved RBC Survival and Hemoglobin Levels

Phase 1 Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of FT-4202, an Allosteric Activator of Pyruvate Kinase-R, in Healthy and Sickle Cell Disease Subjects

Drug-Induced Cytokine Release Sensitizes Protective Tumor Microenvironments to Antibody- Mediated Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only